Interesting discussion of mono vs combination therapies with next generation ALK inhibitors (such as AP26113). I realize this presentation is old, dating from AP26113 early Phase I data, but it made me wonder why I haven't heard more about combination therapies and potential first line use of next generation ALK's. Actually, I'm quite sure the answer is that those discussions are very much going on, but not to the knowledge of lay people like me who see and hear (and let's be honest, understand...) only minuscule fraction of the current scientific evidence in this field.
If others have more recent data and or knowledge of discussions regarding first line and/or combination therapy with AP26113, that would be great if you could share it here...in language that dummies like me can follow.
News 
Market Data 
Discover 
